Nuvation Bio Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
NUVB$4.16-0.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $34,510 | $42,649 |
| Prepaid expenses and other current assets | 6,796 | 1,519 |
| Marketable securities | 562,466 | 568,564 |
| Interest receivable on marketable securities | 4,283 | 3,702 |
| Total current assets | 608,055 | 616,434 |
| Property and equipment, net | 686 | 717 |
| Lease security deposit | 141 | 141 |
| Operating lease right-of-use assets | 3,168 | 3,605 |
| Other non-current assets | 1,075 | 587 |
| Total assets | $613,125 | $621,484 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,436 | $2,209 |
| Current operating lease liabilities | 2,023 | 1,972 |
| Accrued expenses | 11,303 | 9,793 |
| Total current liabilities | 15,762 | 13,974 |
| Warrant liability | 1,812 | 353 |
| Non-current operating lease liabilities | 1,509 | 2,035 |
| Total liabilities | 19,083 | 16,362 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of March 31, 2024 and December 31, 2023. 219,083,219 (Class A 218,083,219, Class B 1,000,000) and 219,046,219 (Class A 218,046,219, Class B 1,000,000) shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 952,807 | 947,745 |
| Accumulated deficit | (357,596) | (342,804) |
| Accumulated other comprehensive loss | (1,169) | 181 |
| Total stockholders’ equity | 594,042 | 605,122 |
| Total liabilities and stockholders’ equity | $613,125 | $621,484 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.